- Conditions
- Infections, Clostridium Difficile
- Interventions
- Blood sampling, Stool sample collection
- Procedure · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Boston, Massachusetts • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- Fidaxomicin
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Vasopressin Deficiency
- Interventions
- Intranasal Oxytocin (IN-OXT), Placebo
- Drug
- Lead sponsor
- Elizabeth Austen Lawson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prediabetes, Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
- Interventions
- CGM Dynamic Index (CDI)
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- CDI
- Interventions
- CDI-risk Classification Tool
- Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13,319 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 60
- States / cities
- Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Clostridioides Difficile Infection
- Interventions
- CRS3123, Active Comparator
- Drug
- Lead sponsor
- Crestone, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 18
- States / cities
- Fullerton, California • Lancaster, California • Mission Hills, California + 14 more
- Conditions
- Arginine Vasopressin Deficiency, Oxytocin Deficiency
- Interventions
- Norethindrone Acetate-Ethinyl Estradiol
- Drug
- Lead sponsor
- Elizabeth Austen Lawson
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clostridium Difficile Infection
- Interventions
- Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
- Conditions
- Diabetes Insipidus, Diabetes Insipidus, Neurohypophyseal
- Interventions
- chlorpropamide, desmopressin
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 6 Months to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- Fidaxomicin, Vancomycin
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Ypsilanti, Michigan
- Conditions
- Chronic Hepatitis C
- Interventions
- CDI-31244, SOF/VEL
- Drug
- Lead sponsor
- Cocrystal Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Clostridium Difficile Infection, Infection, Communicable Diseases
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
- Conditions
- Diarrhea, Clostridium Difficile Infection
- Interventions
- 0.9% Normal Saline, Clostridium difficile toxoid vaccine, Clostridium difficile toxoid vaccine with adjuvant
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Marietta, Georgia • Worcester, Massachusetts + 2 more
- Conditions
- Healthy, Clostridium Difficile Infection
- Interventions
- omeprazole
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Recurrence of Clostridium Difficile Infection
- Interventions
- REBYOTA™
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Chula Vista, California • Murrieta, California + 36 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
- Biological · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
- Interventions
- fluoroquinolone preprescription authorization, Control
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Not listed
- Enrollment
- 5,871 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Standard Practice to Prevent Hospital Onset CDI
- Other
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 148,549 participants
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Clostridium Difficile Infection, Diarrhea
- Interventions
- CB-183,315, Placebo, Vancomycin
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 22
- States / cities
- Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Ridinilazole, Fidaxomicin
- Drug
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Laguna Hills, California • Ventura, California • Idaho Falls, Idaho + 2 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- RBX2660, Standard of Care Antibiotics
- Biological · Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
- Conditions
- Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
- Interventions
- CP101
- Biological
- Lead sponsor
- Finch Research and Development LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 53
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
- Interventions
- VE303, Placebo
- Biological
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more